Clinical utility and patient adherence with ebastine for allergic rhinitis

• Main Author: Giorgio Ciprandi
• Format: Article
• Language: English
• Published: Dove Medical Press 2010-10-01
• Series: Patient Preference and Adherence
• Online Access: http://www.dovepress.com/clinical-utility-and-patient-adherence-with-ebastine-for-allergic-rhin-a5507

Giorgio CiprandiDepartment of Internal Medicine, San Martino Hospital, Genoa, ItalyAbstract: Allergic rhinitis (AR) is a high prevalence disease, affecting 10%–20% of the general population. AR is sustained by an IgE-mediated reaction, and by a complex inflammatory network of cells, mediators, and cytokines, becoming chronic when exposure to allergen persists. A Th2-biased immune response is the basis for the allergic inflammation. Histamine plays a relevant role in symptom occurrence. Therefore, antihistamine use represents a cornerstone in AR management. Ebastine, a novel antihistamine, is effective overall in controlling symptoms, and its safety profile is good. Recently, a new formulation has been developed, ie, a fast-dissolving tablet. Several studies have demonstrated its favorable characteristics. In conclusion, ebastine is an effective and well tolerated antihistamine that may be prescribed for the treatment of AR. The fast-dissolving tablet formulation provides a new option which may be particularly convenient for the patient.Keywords: allergic rhinitis, histamine, antihistamines, ebastine, tablets